Imprimis Pharma (IMMY) Reports Q3 Loss of $0.29/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IMMY Hot Sheet
Join SI Premium – FREE
Imprimis Pharma (NASDAQ: IMMY) reported Q3 EPS of ($0.29), versus ($0.41) reported last year. Revenue for the quarter came in at $4.9 million, versus $2.7 million reported last year.
For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Envista Holdings Corp. (NVST) Tops Q3 EPS by 4c, Beats on Revenue; Offers FY26 Guidance
- Cognex Corp (CGNX) Tops Q3 EPS by 1c, Misses on Revenue; Offers FY26 Guidance
- Tutor Perini (TPC) Tops Q3 EPS by 92c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
